The shadow of Iressa lingered over the FDA Oncologic Drugs Advisory Committee as the panel voted down Genasense (Genta Inc.) and RSR13 (Allos Therapeutics Inc.) at its May 3 meeting. If anyone thought the bar had been lowered for drug approvals, they were mistaken.
Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says.
FDA developing guidelines for oncology endpoints.
Also in this 8-page issue: NIH Conflict of Interest panel recommends that NIH employees should not receive stock options or equities as compensation for outside work.
Michelle Le Beau named director of University of Chicago Cancer Research Center.
Funding opportunities listed.
Trending Stories
- Backlog of work grows at NIH as staff members are being hounded to quit
- In the Headlines: What are Jay Bhattacharya’s plans for NIH?
- Rathmell: My mentor recognized a cliff I was going to fall off before I did.
“He was there to stand with me while I fell, and then made me look up and see that I needed to lean into the experience.” - The Directors: Ray DuBois and Roy Jensen on how COE guides cancer care in rural America
“We’re just going to have to ride through this and not give up.” - In support of three coordinated CCSG components reducing our national burden of cancer
- In the Headlines: Could “flooding the zone” drown NIH and cancer centers?
